Depression in Parkinson's disease: A double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation
Depression in Parkinson's disease: A double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation
复制标题
DOI：
10.1016/j.jad.2008.03.008
复制
发表时间：
2008-12-01
影响因子：
6.6
通讯作者：
Ferraz, Anete Curte
中科院分区：
文献类型：
--
作者：
da Silva, Ticyana Moralez;Munhoz, Renato Puppi;Ferraz, Anete Curte
背景资料：补充鱼油对帕金森病合并抑郁症患者的影响（采用Montgomery-Asberg评定量表（MADRS））。临床总体印象量表（CGI）和贝克抑郁量表（Beck）。方法：采用双盲、安慰剂对照研究，对31例帕金森病合并重度抑郁症（DSM-IV）患者的抑郁情况进行分析。将患者双盲分为两组，分别服用鱼油（含omega-3脂肪酸）或矿物油胶囊，疗程3个月；每组又分成两组：一组服用抗抑郁药物，另一组不服用。结果：29例患者完成了为期12周的试验，其中58%为女性，平均年龄为64.4岁，补充鱼油的患者MADRS和CGI-Depression评分显著降低，BDI组间无差异。14例患者（42%）符合>= MADRS评分降低50%的标准，7例患者（22%）符合缓解标准（最终MADRS总分）
Back-round: Effect of fish oil supplementation in parkinsonian patients with depression measured by Montgomery-Asberg Rating Scale (MADRS). the Clinical Global Impressions Scale (CGI) and Beck Depression Inventory (BECK).Method: Double-blind, placebo-controlled study analyzed depression in 31 patients with Parkinson's Disease and Major Depression (DSM-IV) The patients were double-blind separated in 2 groups that received fish oil (containing omega-3 fatty acids) or mineral oil capsules for 3 months; each group was separated in 2 new groups: one taking antidepressant medication and another one not taking it.Results: 29 patients completed the 12-week trial, 58% were female and the mean age was 64.4 years old, Patients supplemented with fish oil showed a significant decrease in MADRS and CGI-Depression scores, and there was no difference among groups in BDI. 14 patients (42%) met criteria for >= 50% reduction in MADRS score, 7 patients (22%) met criteria for remission (final MADRS total score